
## **Product Data Sheet**

## PerCP/Cy5.5 anti-human HLA-DR

Catalog # / Size:	2235095 / 25 tests 2235100 / 100 tests
Clone:	LN3
Isotype:	Mouse lgG2b, κ
Immunogen:	human PBL
<b>Reactivity:</b>	Human
Preparation:	The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Concentration:	Lot-specific



Human peripheral blood lymphocytes were stained with HLA-DR (clone LN3) PerCP/Cy5.5 (filled histogram) or mouse IgG2b, κ PerCP/Cy5.5 isotype control (open histogram).

## **Applications:**

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 $\mu$ l per million cells or 5 $\mu$ l per 100 $\mu$ l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:	Additional reported applications (for the relevant formats) include: immunohistochemical staining <sup>1</sup> of frozen sections and formalin-fixed paraffin- embedded sections <sup>1</sup> , and immunoprecipitation <sup>1</sup> .
Application References:	<ol> <li>Levacher M, <i>et al.</i> 1990. <i>Clin. Exp. Immunol.</i> 81:177.</li> <li>Terstappen L, <i>et al.</i> 1990. <i>J. Leuk. Biol.</i> 48:138.</li> <li>Edwards J, <i>et al.</i> 1985. <i>J. Immunol.</i> 137:490.</li> <li>van Es A, <i>et al.</i></li> </ol>
Description:	The LN3 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD $\alpha$ (heavy) chain and a 27 kD $\beta$ (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4 <sup>+</sup> T cells.
Antigen References:	<ol> <li>Levacher M, <i>et al.</i> 1990. <i>Clin. Exp. Immunol.</i> 81:177.</li> <li>Terstappen L, <i>et al.</i> 1990. <i>J. Leuk. Biol.</i> 48:138.</li> <li>Edwards J, <i>et al.</i> 1985. <i>J. Immunol.</i> 137:490.</li> <li>van Es A, <i>et al.</i></li> </ol>

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com